Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03529084
Brief Title: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

First Submitted : April 18, 2018
First Submitted that Met QC Criteria : May 7, 2018
First Posted : May 18, 2018

Last Update Submitted that Met QC Criteria : November 21, 2019
Last Update Posted : November 22, 2019